Key points are not available for this paper at this time.
Treatment with epratuzumab 2400 mg cd was well tolerated in patients with moderately to severely active SLE, and associated with improvements in disease activity. Phase III studies are ongoing.
Wallace et al. (Sat,) studied this question.